Frequency of Class I and II HLA alleles in patients with lung cancer according to chemotherapy response and 5-year survival

ARAZ, Ömer; YILMAZEL UÇAR, Elif; MERAL, Mehmet; Yalcin, Aslihan; ACEMOĞLU, Hamit; DOĞAN, Hasan; KARAMAN, Adem; AYDIN, Yener; Gorguner, Metin; AKGÜN, Metin

doi:10.1111/crj.12143

Frequency of Class I and II HLA alleles in patients with lung cancer according to chemotherapy response and 5-year survival

ARAZ Ö., YILMAZEL UÇAR E., MERAL M., Yalcin A., ACEMOĞLU H., DOĞAN H., ...Daha Fazla

CLINICAL RESPIRATORY JOURNAL, cilt.9, sa.3, ss.297-304, 2015 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 9 Sayı: 3
Basım Tarihi: 2015
Doi Numarası: 10.1111/crj.12143
Dergi Adı: CLINICAL RESPIRATORY JOURNAL
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.297-304
Anahtar Kelimeler: Class I and II HLA alleles, lung cancer, response to chemotherapy, survival, INFLAMMATORY FACTOR-I, PROGNOSTIC-FACTOR, DRUG-RESISTANCE, SOLID TUMORS, EXPRESSION, ANTIGEN, CARCINOMA, VIVO, PROLIFERATION, INTERFERON
Atatürk Üniversitesi Adresli: Evet

Özet

IntroductionLung cancer is the most common cause of cancer death in the world, and the most common type is non-small-cell lung cancer (NSCLC). At present, surgical resection, chemotherapy, and radiation therapy are the main treatments for patients with NSCLC, but unfortunately outcome remains unsatisfactory.